Literature DB >> 25331784

Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.

Ayumu Taguchi1, Oliver Delgado, Müge Celiktaş, Hiroyuki Katayama, Hong Wang, Adi F Gazdar, Samir M Hanash.   

Abstract

p53 is commonly mutated in lung adenocarcinoma. Mutant p53 loses wild-type function and some missense mutations further acquire oncogenic functions, while p53 wild-type may also induce pro-survival signaling. Therefore identification of signatures based on p53 mutational status has relevance to our understanding of p53 signaling pathways in cancer and identification of new therapeutic targets. To this end, we compared proteomic profiles of three cellular compartments (whole-cell extract, cell surface, and media) from 28 human lung adenocarcinoma cell lines that differ based on p53 mutational status. In total, 11,598, 11,569, and 9090 protein forms were identified in whole-cell extract, cell surface, and media, respectively. Bioinformatic analysis revealed that representative pathways associated with epithelial adhesion, immune and stromal cells, and mitochondrial function were highly significant in p53 missense mutations, p53 loss and wild-type p53 cell lines, respectively. Of note, mRNA levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α), a transcription coactivator that promotes mitochondrial oxidative phosphorylation and mitochondrial biogenesis, was substantially higher in p53 wild-type cell lines compared to either cell lines with p53 loss or with missense mutation. Small interfering RNA targeting PGC1-α inhibited cell proliferation in p53 wild-type cell lines, indicative of PGC1-α and its downstream molecules as potential therapeutic targets in p53 wild-type lung adenocarcinoma.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Lung adenocarcinoma; PGC-1α; Systems Biology; Transcriptomics; p53

Mesh:

Substances:

Year:  2014        PMID: 25331784      PMCID: PMC4403731          DOI: 10.1002/pmic.201400378

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  47 in total

1.  A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC).

Authors:  Shao-En Ong; Matthias Mann
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  p53 regulates mitochondrial respiration.

Authors:  Satoaki Matoba; Ju-Gyeong Kang; Willmar D Patino; Andrew Wragg; Manfred Boehm; Oksana Gavrilova; Paula J Hurley; Fred Bunz; Paul M Hwang
Journal:  Science       Date:  2006-05-25       Impact factor: 47.728

Review 3.  The dark side of a tumor suppressor: anti-apoptotic p53.

Authors:  R U Jänicke; D Sohn; K Schulze-Osthoff
Journal:  Cell Death Differ       Date:  2008-03-21       Impact factor: 15.828

4.  Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production.

Authors:  Juan M Funes; Marisol Quintero; Stephen Henderson; Dolores Martinez; Uzma Qureshi; Claire Westwood; Mark O Clements; Dimitra Bourboulia; R Barbara Pedley; Salvador Moncada; Chris Boshoff
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-23       Impact factor: 11.205

5.  Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.

Authors:  Béatrice Eymin; Sylvie Gazzeri; Christian Brambilla; Elisabeth Brambilla
Journal:  Oncogene       Date:  2002-04-18       Impact factor: 9.867

6.  Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.

Authors:  Yu-Chien Wang; Ruo-Kai Lin; Yi-Hung Tan; Jung-Ta Chen; Chih-Yi Chen; Yi-Ching Wang
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

Review 7.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

8.  MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.

Authors:  M Higashiyama; O Doi; K Kodama; H Yokouchi; T Kasugai; S Ishiguro; K Takami; T Nakayama; I Nishisho
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

9.  Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2.

Authors:  Changgong Li; Hongyan Chen; Lingyan Hu; Yiming Xing; Tomoyo Sasaki; Maria F Villosis; John Li; Michiru Nishita; Yasuhiro Minami; Parviz Minoo
Journal:  BMC Mol Biol       Date:  2008-01-23       Impact factor: 2.946

10.  Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.

Authors:  Vitor M Faça; Aviva P Ventura; Mathew P Fitzgibbon; Sandra R Pereira-Faça; Sharon J Pitteri; Ann E Green; Renee C Ireton; Qing Zhang; Hong Wang; Kathy C O'Briant; Charles W Drescher; Michèl Schummer; Martin W McIntosh; Beatrice S Knudsen; Samir M Hanash
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

View more
  12 in total

Review 1.  Functional variomics and network perturbation: connecting genotype to phenotype in cancer.

Authors:  Song Yi; Shengda Lin; Yongsheng Li; Wei Zhao; Gordon B Mills; Nidhi Sahni
Journal:  Nat Rev Genet       Date:  2017-03-27       Impact factor: 53.242

2.  Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.

Authors:  Müge Çeliktas; Ichidai Tanaka; Satyendra Chandra Tripathi; Johannes F Fahrmann; Clemente Aguilar-Bonavides; Pamela Villalobos; Oliver Delgado; Dilsher Dhillon; Jennifer B Dennison; Edwin J Ostrin; Hong Wang; Carmen Behrens; Kim-Anh Do; Adi F Gazdar; Samir M Hanash; Ayumu Taguchi
Journal:  J Natl Cancer Inst       Date:  2017-03-01       Impact factor: 13.506

Review 3.  PGC-1 Coactivators: Shepherding the Mitochondrial Biogenesis of Tumors.

Authors:  Chi Luo; Hans R Widlund; Pere Puigserver
Journal:  Trends Cancer       Date:  2016-10

Review 4.  Functional characterization of AMP-activated protein kinase signaling in tumorigenesis.

Authors:  Ji Cheng; Tao Zhang; Hongbin Ji; Kaixiong Tao; Jianping Guo; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2016-09-25

Review 5.  F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.

Authors:  Ammar Sukari; Irfana Muqbil; Ramzi M Mohammad; Philip A Philip; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2016-01-21       Impact factor: 15.707

Review 6.  Peroxisome Proliferator-Activated Receptor γ and PGC-1α in Cancer: Dual Actions as Tumor Promoter and Suppressor.

Authors:  Seong-Hoon Yun; Sang-Heum Han; Joo-In Park
Journal:  PPAR Res       Date:  2018-01-21       Impact factor: 4.964

Review 7.  p53 and metabolism: from mechanism to therapeutics.

Authors:  Fernando M Simabuco; Mirian G Morale; Isadora C B Pavan; Ana P Morelli; Fernando R Silva; Rodrigo E Tamura
Journal:  Oncotarget       Date:  2018-05-04

Review 8.  When tumor doesn't read textbook. Third case of TTF1 and p40 co-expression in the same tumour cells in a non-small cell carcinoma. A potential new entity to consider?

Authors:  M Spinelli; J Khorshad; P Viola
Journal:  Pathologica       Date:  2019-06

9.  Protein citrullination as a source of cancer neoantigens.

Authors:  Hiroyuki Katayama; Makoto Kobayashi; Ehsan Irajizad; Alejandro Sevillarno; Nikul Patel; Xiangying Mao; Leona Rusling; Jody Vykoukal; Yining Cai; Fuchung Hsiao; Chuan-Yih Yu; James Long; Jinsong Liu; Franscisco Esteva; Johannes Fahrmann; Sam Hanash
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

10.  Repeated PM2.5 exposure inhibits BEAS-2B cell P53 expression through ROS-Akt-DNMT3B pathway-mediated promoter hypermethylation.

Authors:  Wei Zhou; Dongdong Tian; Jun He; Yimei Wang; Lijun Zhang; Lan Cui; Li Jia; Li Zhang; Lizhong Li; Yulei Shu; Shouzhong Yu; Jun Zhao; Xiaoyan Yuan; Shuangqing Peng
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.